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abstract: The recent introduction of oocyte vitrification has significantly advanced the outcome of oocyte cryopreservation, leading to
clinical results comparable to those achieved in IVF using fresh oocytes, as reported by experienced centres. This has lead to new debate,
both in the professional community and in society at large, about the acceptability of offering this technology to reproductively healthy
women who want to cryopreserve their oocytes against the threat of time. Given the many demands calling for simultaneous realization
in a relatively short period of their lives, many women who want to have children feel to be under considerable pressure. The option of
oocyte cryopreservation may in fact give them more breathing space. In this document, it is concluded that the arguments against allowing
this application of the technology are not convincing. The recommendations include the need for adequate information of women interested
in oocyte cryopreservation, also in order to avoid raising false hopes. The message must remain that women’s best chances of having a
healthy child are through natural reproduction at a relative early age. Centres offering this service must have the necessary expertise to
employ oocyte cryopreservation efficiently with the so far non-standardized protocols. As data about long-term safety is still lacking,
centres also have a responsibility to contribute to the collection of these data.
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Introduction
The recently established possibility of effectively cryopreserving
functional oocytes through vitrification promises to revolutionize
IVF practice. One new option is that of women using this technol-
ogy to protect their reproductive potential against the threat of
time. This document analyses the ethical arguments about the ac-
ceptability of this option. In an earlier statement the Task Force
concluded that ‘oocyte freezing for fertility preservation without
a medical indication should not be encouraged’ (Shenfield et al.,
2004). In the light of new scientific developments, and after con-
sidering relevant ethical arguments, the Task Force now takes
the view that oocyte cryopreservation to improve prospects of
future child bearing should also be available for non-medical
reasons.
Background and facts
Effectiveness and safety of oocyte
cryopreservation
The inefficiency of conventional slow-freezing techniques has for
decades prevented the widespread implementation of oocyte cryo-
preservation in clinical practice. The introduction of oocyte vitrification
significantly advanced the outcome of oocyte cryopreservation result-
ing in outcomes comparable to those achieved with fresh oocytes, as
reported by experienced centres (Cobo et al., 2010; Rienzi et al.,
2010). A large randomized clinical trial demonstrated that the effect-
iveness of vitrified oocytes is non-inferior to fresh oocytes in terms
of ongoing pregnancy rates in an oocyte donation programme
(Cobo et al., 2010). Data from peer-reviewed literature conclude in
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a 4–5% live birth rate per vitrified oocyte in women under the age of
36 years (Oktay et al., 2006; The Practice Committee of the SART and
ASRM, 2008), meaning that one live birth is to be expected on average
per 20–25 vitrified oocytes.
From the current data, it appears that vitrification is more efficient
than slow freezing. Vitrification is achieved by combining a high con-
centration of cryoprotectants with high cooling and warming rates.
Unlike slow freezing, vitrification results in the complete elimination
of ice crystal formation avoiding the main cause of cryopreservation
injury. These high cooling and warming rates are usually achieved by
the use of open systems in which the samples are put into direct
contact with liquid nitrogen during vitrification, allowing possible con-
tamination. Aseptic modifications for open system vitrification, such as
ultraviolet liquid nitrogen sterilization, have been described by
Parmegiani et al. (2011) and recent observational data report highly
efficient oocyte vitrification using high security closed vitrification
devices (Stoop et al., 2011a).
In a recent systematic review of 22 observational studies examining
the neonatal health of children born after slow freezing of oocytes
(Wennerholm et al., 2009), the authors found limited information
on birthweight or karyotype examinations and in most studies the
only information given regarding childrens’ well-being was ‘healthy’.
A large study by Chian et al., (2008) found reassuring evidence that
pregnancies and infants conceived following oocyte vitrification are
not associated with increased risk or adverse obstetric and perinatal
outcomes. A literature review by Noyes et al. (2009), comprising all
(900) verified live born infants resulting from assisted reproduction
using cryopreserved oocytes, concluded that compared with naturally
conceived infants, there was no difference in the rate of congenital
anomalies. Although current data seem reassuring, there is no data
available on the long-term child follow-up.
Potential users’ interest
Until now, only limited research has been done into attitudes towards
oocyte cryopreservation for ‘social reasons’ among women of repro-
ductive age. The outcomes of a recent Belgian study suggest that a sig-
nificant proportion of young women would consider safeguarding their




The principle of beneficence (‘doing good’) belongs to the Hippocratic
core of medical ethics. It is traditionally related to an account of the
good of medicine understood as preventing and curing disease (and
caring for the ill). Reproductive medicine is widely regarded as fitting
in with this medical model, even though many fertility treatments do
not restore natural fertility but aim at avoiding the consequence (invol-
untary childlessness) of compromised reproductive functions. Other
things being equal, fertility preservation for women at risk of disease
related or iatrogenic premature menopause can be accounted for in
terms of this model as an unproblematic instance of medical benefi-
cence. But, what about fertility preservation for women who fear
natural fertility loss? As female fertility loss around the age of 40–45
is a natural phenomenon, this application of the technology would
seem to fall outside the scope of the medical model. If so, should
doctors not refrain from fulfilling such requests? There are two pos-
sible rejoinders to this. One is that the appeal to the traditional
limits of the profession ignores that in reality the practice of medicine
comprises many activities that would then also have to be questioned.
In the field of reproduction, one may think of sterilization, abortion
and donor insemination for single or lesbian women. If those activities
are acceptable in principle, it is difficult to maintain that things would
be different with regard to fertility preservation for non-medical
reasons. The second, more fundamental, argument is that the
appeal to the limits of medicine wrongly suggests that notions of
health and disease can simply be inferred from facts about biological
functioning without reference to socially mediated understandings
(Richman, 2004). That this is not the case is quite obvious from the
intractable nature of debates about whether and under what condi-
tions infertility should be regarded as an instance of ill health. More-
over, certain accepted applications of reproductive medicine are
better understood as a treatment for involuntary childlessness,
period, regardless of whether this condition is the consequence of a
biological or functional defect. IVF for ‘idiopathic infertility’ (currently
one of the most frequent indications) is a good example. Under this
heading, many couples are being treated whose subfertility is a conse-
quence of natural ovarian ageing: the fact that the female partner has
approached the end of her reproductive life span. If this is confirmed
by a poor oocyte yield, many centres offer such couples the opportun-
ity of IVF with donor oocytes, at least for a few more years. Neverthe-
less, these treatments are regarded as beneficence-based responses
to a medical indication. This presupposes a wider understanding of re-
productive health in the light of which fertility preservation for ovarian
ageing cannot so easily be dismissed as a non-health-related
preference.
Respect for reproductive autonomy
Even when one accepts that a strict demarcation between medical and
social needs cannot be drawn in the field of assisted reproduction, one
may still ask whether fertility specialists should go along with all
requests for fertility preservation. Fertility preservation for women
at risk of disease related or iatrogenic premature menopause clearly
falls within the scope of reproductive medicine. The same can arguably
be said of fertility preservation for women who want to have children
and are still without a partner at the age of 35. Their request is under-
standable, given that there is a reasonable chance beyond their own
control that they will remain childless. But what about requests
from women who deliberately choose to postpone childbearing
while giving temporary priority to other life goals such as the
build-up of a career? Can one still say in such cases that fertility pres-
ervation is needed to avoid involuntary childlessness? How involuntary
would that condition be if it results from the woman’s own choices?
Instead of going along with such requests, should fertility specialists
not simply tell these women to reconsider their priorities?
There are several problems with this view. For one thing, the sug-
gestion that, in the case of the ‘career woman’, there is no real need
for fertility preservation is psychologically questionable. It neglects the
intrinsic connection between a person’s most central life projects and
his or her sense of identity and how this connection may present as a
form of personal necessity (Williams, 1985). This means that the
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postponement choices of the ‘career women’ need not make her
eventual childlessness less involuntary. Moreover, it should be
acknowledged that not yet having a partner with whom to have chil-
dren may also be a consequence of a strong focus on one’s career
(Nekkebroeck et al., 2010). This means that the two groups of pos-
sible beneficiaries referred to in this debate are overlapping rather
than distinct and that the postponing ‘career woman’ is not so
deviant a character as many seem to think. Postponement of child-
bearing is not a new phenomenon that only comes into play with
the improvements in oocyte cryopreservation. In fact, it explains a
large part of the current need for IVF. If one accepts to treat deliberate
postponers, one should also help them to save their oocytes at an
earlier age as a form of prevention. To the extent that concerns
about this development are also about avoidable risks and costs,
these issues will be discussed below. But the fact that, in this
debate, there is much more sympathy with women who find them-
selves without a partner than with those who want to give priority
to their career or other life plans, seems to point beyond such con-
cerns about risks and costs to traditional beliefs regarding the
proper place of childbearing in a woman’s life. In a secular debate,
the problem with arguing from views about ‘the good life’ is that
they rest on religious or naturalistic presuppositions that not all parti-
cipants necessarily share. As imposing such views on others is morally
unacceptable, fertility specialists should leave it to the women them-
selves to make their own informed decisions about the need for fer-
tility preservation. Indeed, doing so is in line with the ethical principle
of respect for the autonomy of persons. It is accepted that competent
persons have the right to make their own reproductive decisions, in-
cluding whether to have children, with whom, how many, etc. It would
seem that this also includes the right to decide about when to repro-
duce and what priority to give to childbearing in relation to other life
plans.
Non-maleficence
Obtaining oocytes for fertility preservation requires a medical proced-
ure (ovarian stimulation, oocyte pick-up) that is burdensome for the
woman and not entirely without risk of complications. Whether this
is acceptable in view of the principle of non-maleficence (‘first do
no harm’) depends on the proportionality of the necessary proce-
dures. On the one hand, the risks of bleeding and infection are ex-
tremely small (Vercammen et al., 2011) and the occurrence of the
ovarian hyperstimulation syndrome is almost fully avoidable
(Devroey et al., 2011). In regular IVF, these procedural risks are
regarded as clearly outweighed by the benefits of the treatment. In fer-
tility preservation, on the other hand, it is far from certain that the
woman will eventually use her cryopreserved oocyte reserve for re-
production. It should also be taken into account that a woman who
at around 35 would want to have a reasonable number of oocytes
cryopreserved will need to undergo several stimulation cycles.
These are proportionality affecting considerations that should certainly
be discussed with requesting women as part of proper counselling.
However, the importance of keeping open the prospect of having chil-
dren later in their lives, and how this weighs up to the burdens and
risks of repeated stimulation and oocyte-pick up can only be deter-
mined individually by the women concerned. A paternalistic attitude
from the physician should be rejected. That a fertility centre may
still decide not to start treatment for reasons of cost-effectiveness
and scarcity of resources is a different matter.
Centres offering this service must have the necessary expertise to
employ oocyte cryopreservation efficiently with the so far non-
standardized protocols. If not, harm may be done to women who mis-
takenly expect to be able to use good quality oocytes for reproduction
at a later time. Any burdens, risks and costs may then turn out to have
been disproportional.
In the quoted study on a group of potential users, women referred
to reproductive safety as a determining factor in their decision-making
about fertility preservation (Stoop et al., 2011b). The health of any
future children born as a result of reproductive technologies should
also be a paramount concern of fertility specialists and clinics (Pennings
et al., 2007). Although the number of children born from cryopre-
served oocytes is still small, there is no indication that they would
be at increased risk of adverse health outcomes. But more data are
clearly needed. These should not only be based on short-term, but
also on medium- and long-term follow-up of children. Centres offering
this novel technology have a responsibility to contribute to the collec-
tion of these data (Dondorp and de Wert, 2011).
In the debate about fertility preservation for ovarian ageing, con-
cerns have also been raised about possible risks of reproduction at
a later age. One may think here not only of a higher risk of pregnancy
complications, but also of putting the future child at risk of negative
psychosocial consequences of having to grow up with older parents.
Earlier, these same concerns have been raised with regard to IVF
using donor oocytes in peri- and post-menopausal women.
However, in well-selected healthy women pregnancy risks are not
prohibitively higher up to the age of at least 50 (Sauer et al., 1995;
Sauer et al., 1996; Paulson et al., 2002; Chibber, 2005). With regard
to the welfare of the child, helping older women to have children
need not be irresponsible as long as at least one of the parents can
be expected to remain healthy enough to meaningfully fulfill the par-
ental role up until the child reaches adulthood (Health Council of
the Netherlands, 1997). Moreover, older parents have some advan-
tages (relational stability, parent–child interactions, financial situation,
etc.) compared with younger parents (Pennings, 1995). Given that
most women who want to have oocytes cryopreserved for later use
aim to buy some extra years allowing them to have children in the
early years of their fourth decade (Stoop et al., 2011b), there is no
unacceptable risk either for themselves or their future children.
Compared with current options of trying to get pregnant in the
fourth decade, using one’s own stored, young oocytes may in fact
have important benefits for the women involved. Compared with
IVF with donor oocytes, there is a clear benefit in the prospect of
having a child that is genetically one’s own. And compared with
using one’s own fresh but age-compromised oocytes, the benefits
are a higher success rate and a lower rate of oocyte-related health
risks for the offspring, especially chromosomal abnormalities.
Justice and societal implications
In relation to the life expectancy of modern humans, women stand to
lose their natural fertility at a relatively early age. Given the many
demands calling for simultaneous realization in a relatively short
period of their lives, many women who want to have children feel
to be under considerable pressure. The option of oocyte
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cryopreservation may give them more breathing space. For men, the
combination of fatherhood with other life plans is not as difficult.
Not only do they tend to leave most of the burdens of daily care to
their partners, but they also have the opportunity to reproduce until
much later in their lives. Moreover, men already can have their
sperm cryopreserved. This is done for medical reasons, but sperm
banking is also commercially available as a means of preserving repro-
ductive capacity to men in jobs or sports that pose a possible threat to
their fertility. From a feminist perspective, therefore, the availability of
options for female fertility preservation can be regarded as an import-
ant step towards greater reproductive justice (Goold and Savulescu,
2009; Homburg et al., 2009).
Others have objected that as a solution to women’s problems with
having their children earlier in life, fertility preservation is a typical in-
stance of ‘medicalization’: the tendency to seek medical answers to
societal problems. The problem here is that many modern societies
are organized in ways that make it difficult for women to have children
at what would biologically be the best age for reproduction. According
to these critics, offering fertility preservation to healthy women will
lead to undermining efforts aimed at addressing the societal cause
of the high maternity age, thus only reinforcing and perpetuating the
problem. But however important it is to create better conditions for
combining early childbearing with the pursuit of other life plans and
also to educate young women that their chances of successful repro-
duction and healthy children are greatest when they start early, all this
should not lead to ignoring the plight of those who find themselves
caught in the trap of time. That, indeed, would be unjust. Moreover,
there is no good reason for not doing both: stimulate early childbear-
ing while allowing fertility preservation for those who need or want
extra time.
The precise societal implications of fertility preservation for ovarian
ageing not only depend on the number of women who will make use
of this option, but also on how having a stored reserve will affect re-
productive decisions and possible outcomes. Different scenarios need
to be distinguished: (i) women who would otherwise have remained
childless or who because of their age would have had no other
option than reproduction with the use of donor oocytes can still
have their genetically related child (or children); (ii) women who
would otherwise have used their last chance of having a child
through IVF with their own fresh oocytes can use their (biologically
younger) cryopreserved oocytes instead, thereby enlarging their
chances of success and reducing the risk of having a child with a
chromosomal abnormality and (iii) women who would otherwise
have had their children at an age where natural conception was still
possible can choose to postpone childbearing until after the loss of
natural fertility.
It is important to note that only the last of these scenarios involves
what the critics of this development seem to fear, namely that (rela-
tively) early and natural reproduction will come to be replaced by
assisted reproduction at a later stage in women’s lives. This indeed
entails higher costs and a higher complication rate and may also lead
to a higher rate of involuntary childlessness than would otherwise
have been the case. However, the comparison presupposes that
natural reproduction would have been a realistic option for the
women involved. Where this is not the case, the other scenarios
show that the option of using a cryopreserved reserve may in fact
bring important benefits, not just to individual women (and their
partners) but also to society. Societal benefits include the birth of add-
itional children at a time of declining population birth rates in devel-
oped countries, a lower dependency on the use of donor oocytes
(avoiding extra costs and psychosocial complications) and more cost-
effective IVF in older women, with a lower rate of chromosomal ab-
normalities (Mertes and Pennings, 2012).
A further scenario is that of women cryopreserving a sufficient
number of oocytes for later but without ever using this reserve,
either because they find a partner when natural reproduction is still
possible, or because they decide not to have children after all. For
the women involved an important benefit may still be that having a
stored, healthy oocyte reserve takes away much of the time pressure
both on creating the conditions for starting a family, including court-
ship, and on the realization of other life plans. Moreover, left-over
oocytes can still be used for donation either for infertility treatment
or for scientific research. In fact, the greater availability of donor




When offering oocyte cryopreservation for age-related fertility loss,
professionals and clinics should avoid presenting this option as a
warrant for successful future reproduction (Harwood, 2009). Fertility
preservation should be discussed for what it is: an emergency measure
for women who fear not to be able to have their children before
running out of functional oocytes. Having a stored reserve will give
them the prospect of a limited number of IVF cycles at a later stage
of their life, which may or may not lead to a child. In order to avoid
raising false hopes, professionals should tell women that their best
chances of having a child are through natural reproduction at a relative
early age. It would also be relevant for them to know the percentage
of women who eventually make no use of their stored reserve.
Women interested in oocyte cryopreservation should be adequate-
ly informed about the nature, burdens and risks of the procedure, the
conditions under which their oocytes can be stored, the time frame
within which they can be used, and the costs of procedure, storage
and use. They should also be provided with an estimate of their
chances of successful reproduction. This requires state of the art
data about the expected oocyte yield per stimulation cycle and the
percentage of life-born children per cryopreserved oocyte, stratified
for women of different ages and with different ovarian reserve test
results, taking account of the literature regarding the use of specific
cryopreservation techniques (like vitrification or slow freezing). This
information should also relate to the expertise and efficiency of the
centre. Women should be informed that oocyte cryopreservation is
a relatively new technology, that the number of children born from
such oocytes is still limited and that follow-up data regarding any pos-
sible offspring health risks are still being collected.
As a precondition for informed decision-making, women interested
in oocyte cryopreservation should be made aware of the possibility of
considering alternatives with different profiles of advantages and disad-
vantages. This not only includes the future use of donor oocytes but
also alternative forms of fertility preservation, e.g. involving cryo-
preservation of ovarian tissue or embryos. The former of these
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approaches has the theoretical advantage of making a larger number of
oocytes available for postponed reproduction. However, this ap-
proach to fertility preservation has also been introduced relatively re-
cently and the number of children born is still very limited. Embryo
cryopreservation has the advantage of being an established technol-
ogy, but this approach would seem to be interesting only for
women in a stable relationship (Dondorp and De Wert, 2009).
Age limits
Women interested in fertility preservation should be advised that the
cryopreservation procedure should ideally be done at a relatively early
age and if possible prior to the age of 35, being the age limit generally
used for oocyte donor recruitment. Although cryopreservation for
women .38 should not be recommended, there may be cases
where a prior assessment of the ovarian reserve justifies the proced-
ure. Counselling based on an individual assessment of the available re-
productive potential would seem to be the best approach. At present,
the average age of women deciding to save their oocytes for later is 38
(Gold et al., 2006; Klein et al., 2006; Sage et al., 2008).
With regard to the time frame for using one’s stored reserve,
setting an age limit at around 50 would seem to be justifiable in the
light of considerations already referred to. It could be argued that
for women with a younger partner the line may be drawn higher, as
there would then be at least one parent who can be expected to
be able to guide the child into adulthood. In any case, however,
there is no good reason for drawing a line here that is different
from that regarding IVF using donor oocytes.
Coverage
In countries where assisted reproduction is (partly) covered within the
healthcare system, the question will arise who should pay for fertility
preservation for ovarian ageing. A distinction should be made between
the stages of stimulation and cryopreservation on the one hand, and
that of reproduction (use) on the other. With regard to the reproduc-
tion stage, it seems clear that women who are no longer able to con-
ceive naturally but who have a stored oocyte reserve that they want to
use in IVF treatment would be eligible to have that treatment funded
on conditions that are the same as those that currently hold for other
fertility patients. Depending on those conditions, coverage should be
expected for reproduction until the woman has reached the early
years of her fourth decade. With regard to reimbursing treatment
of women after that age, further debate will be necessary. As
natural childbearing becomes more exceptional later in the fourth
decade, many will find it less obvious that society should pay. On
the other hand, it can be questioned whether this appeal to ‘normal
species functioning’ should indeed determine the scope for reimburse-
ment of assisted reproduction. A more practical consideration is that
countries are already struggling to accommodate present IVF demand
in healthcare budgets that are increasingly strained. Still, in many
western societies, there are demographic reasons for welcoming the
birth of any extra child born to women who are socially, economically
and physically able to give it a good start in life.
With regard to the creation and preservation stages, it would seem
logical to expect women to pay for this themselves. After all, they are
reproductively healthy and, unlike women facing premature pathogenic
or iatrogenic fertility loss, there is no obvious medical reason behind
their request. If society does not pay for elective procedures such
as sterilization, why should it pay for fertility preservation? One im-
portant difference is that fertility preservation may be seen as a pre-
ventative measure with the same aim as assisted reproduction:
avoiding unwanted childlessness. But even if in theory there might
be arguments for reimbursing women who decide to cryopreserve
their oocytes for later, these are considerably weakened from a cost-
effectiveness perspective if it turns out that many or even most of
these oocytes will not be used for reproduction. This includes both
the use for the women themselves and the use by others when any
left-over oocytes are subsequently destined for donation to others.
Still, many of those who will eventually use their stored reserve can
be expected to do so at an age when assisted reproduction for
women no longer able to conceive naturally is still covered by the
healthcare system of their countries. In that situation, the fact that
the first and most expensive stage of IVF treatment (obtaining
mature oocytes through hormone stimulation) has already been
done as part of the fertility preservation procedure significantly
reduces the costs to the system, in addition to the clear benefits asso-
ciated with the use of a woman’s own younger oocytes. Against this
background, it has been asked whether it is fair that women who
chose to undergo the first stage of IVF treatment already at a
younger age would not have this part of the procedure reimbursed
if at a later moment in their lives they return for completing the treat-
ment (Stoop, 2010). Proposals to mend this injustice include the offer
of a refund if the woman’s stored oocytes are effectively used for re-
production (either by the woman herself or through donation), and
the offer of additional reimbursed transfer cycles (Mertes and Pen-
nings, 2012).
Cryopreservation and donation
A new question arising with this development is what to do with left-
over oocytes. As with embryos, the possibilities are donation for re-
production, donation for scientific research and destruction.
Women should be informed about these options prior to cryopreser-
vation and be asked to decide on what will happen in case they die or
lose the ability to decide for themselves.
Unless helping a family member or friend is envisaged, most centres
will only use oocytes for donation that were obtained before age 35.
This means that women considering donation also as a means to have
part of their investment refunded in case they would not need the
oocytes themselves should be aware that this will only be possible if
they decide to preserve their oocytes at a relatively early age.
Donation of a limited number of oocytes may also take place in the
context of a ‘freeze and share’ arrangement as developed by a British
fertility centre (Atalla, 2008). Under this arrangement women (under
35 and screened for being in good reproductive shape) do not have to
pay for stimulation, harvesting and the first years of storage in ex-
change for donating half of their oocytes to the programme. The struc-
ture of this arrangement is similar to that of existing ‘egg-sharing’
programmes where women get free IVF treatment in exchange for
part of their oocytes. Arrangements of this type have been criticized
for introducing a covert form of payment for gametes, thus undermin-
ing the ideal of altruistic donation. However, altruistic donation should
not be regarded as an end in itself. Donation in exchange for some-
thing of value to the donor does not as such constitute a moral
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problem. Ethical concerns only arise when donation arrangements
provide a context of exploitation. Although egg-sharing arrangements
are not necessarily exploitative, there is certainly reason to critically
review the conditions set by centres offering this type of service.
Women should be fully informed about all relevant aspects of the ar-
rangement, including the fact that by relinquishing their oocytes, they
will become donors. They should be fully counselled about what it
may mean for them to take that step.
Recommendations
(i) Oocyte cryopreservation should not just be available for women
at risk of premature pathogenic or iatrogenic fertility loss, but
also for those who want to protect their reproductive potential
against the threat of time.
(ii) Fertility specialists should refrain from passing judgement on a
woman’s motives for postponing childbearing and requesting
fertility preservation.
(iii) Centres offering this service must have the necessary expertise
to employ oocyte cryopreservation efficiently. As data about
long-term safety are still lacking, centres also have a responsibil-
ity to contribute to the collection of these data.
(iv) Fertility specialists should be careful not to raise false hopes.
Women interested in oocyte cryopreservation for age-related
fertility loss should be told that their best chances of having a
child are through natural reproduction at a relative early age.
Fertility preservation should be presented as a preventative
measure for those needing or wanting more time that increases
their chances but offers no guarantee of success.
(v) Interested women should be provided with a personalized and
evidence-based estimate of the number of oocytes (and
cycles) they would need for successful reproduction. This infor-
mation should also relate to the expertise and efficiency of the
centre. Although cryopreservation for women .38 should not
be recommended, there may be cases where a prior assessment
of the ovarian reserve justifies the procedure.
(vi) Interested women should be adequately informed about all rele-
vant aspects of the procedure for obtaining the oocytes, the
conditions for storage, time frame for reproductive use and
the options for deciding about the eventual fate of any left-over
oocytes.
(vii) Interested women should be informed that oocyte cryopreser-
vation is a relatively new technology, that the number of children
born from such oocytes is still limited and that long-term safety
is still to be proved.
(viii) More data are needed about the psychosocial aspects of fertility
preservation for ovarian ageing, including women’s motives for
choosing this option, what it means for women to have a
stored reserve and the choices they make regarding the use
of this reserve.
(ix) Policy-makers in countries where IVF is (partly) covered within
the healthcare system should consider how women whose
stored oocytes are eventually used for reproduction can be
compensated.
(x) Women embarking on ‘freeze and share’ arrangements should
be fully counselled about the psychosocial implications of be-
coming an oocyte donor.
(xi) The professions in the field of medically assisted reproduction
should promote and contribute to societal efforts aimed at
raising awareness of age-related female fertility decline among
women and men of reproductive age.
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